FDA PARTNERS for VC & PE Firms

ACCELERATING RETURNS. NAVIGATING THE COMPLEX LANDSCAPE.

Financial metrics only tell half the story. In the 2026+ deal landscape, FDA regulatory risk is a critical driver of asset valuation.

We bridge the gap between financial potential and regulatory reality. We function as an extension of your investment team, validating your thesis before the deal closes and accelerating your portfolio's path to exit.your business to the next level.

THE CORE VALUE: TIME IS REVENUE

In the biotech sector, delays are measured in millions. For a blockbuster asset, every single day on the U.S. market can generate at least ~$1M in profit [1]. Taking an extra 60 days to get FDA approval could cost a portfolio company ~$60M in lost revenue [2].

The Speed Advantage

Our mandate is to stop the cash burn. We specialize in identifying expedited strategies, such as High-Value Designations, to maximize asset valuation and shorten timelines.

Getting "Unstuck"

We intervene when assets stall. We deploy senior expertise to resolve clinical holds and negotiate directly with FDA review divisions to get the product moving again.

THE EXPERTISE: WE WROTE THE TRAINING MANUAL

Navigating the FDA requires more than reading the rules; it requires understanding the people who wrote them.

Former FDA & Industry Leaders

Our team is comprised of former FDA senior officials, industry veterans, and academic stakeholders with 250+ years of combined insight.

Teaching the Regulator

We created internal training materials for FDA Medical Officers and Pre-Market Reviewers that are still used to this day.

Proven Outcomes

We helped over a dozen companies secure marketing authorizations, including the first-ever FDA Breakthrough Device Designation (BDD) for treating Alzheimer’s disease.

HOME
FOR COMPANIES
FOR INVESTORS
OUR TEAM
CONTACT US

FDA Partners

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Decline Accept